30
Huaren Pharmaceutical Co., Ltd.
300110.SZ · SHZ
¥3.18 -0.93% (-¥0.03)
1M +11.62%
Market Cap ¥3.76B
P/E Ratio -
Div. Yield -
ROE 48.21%
Bulios Fair Price
¥2.29
28.0% downside
Current Price
¥3.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 300110.SZ is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
75 /100
Cheap P/B 4.34x
P/FCF 13.78x
P/S 2.89x
Growth
36 /100
Stable FCF growth 24.78%
Book val. growth 30.82%
Rev. growth 6.55%
Profitability
43 /100
Moderate FCF margin 20.95%
Op. margin 34.63%
Gross margin 33.93%
Quality
6 /100
Poor Asset turnover 0.47x
ROA 17.15%
ROIC 23.34%
Debt
27 /100
High Current ratio 0.80x
Int. coverage -10.83x
Debt/Equity 1.13x
Stability
34 /100
Moderate Profitable years 0
EPS volatility 498.30%
Beta 0.28x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 300110.SZ
Online
Sector
Healthcare
Industry
Medical - Specialties
CEO
Li Zhiyong
Employees
2,549
Headquarters
Qingdao